The Maharashtra Food and Drug Administration has initiated a major enforcement action against Cadila Pharmaceuticals Limited, resulting in a ban on the sale and distribution of several of their medical products. This regulatory move stems from significant concerns regarding the similarity in brand names, which authorities believe could lead to potential medication errors by doctors, pharmacists, and patients. In addition to the sales ban, officials confirmed the seizure of pharmaceutical stock valued at approximately 2.45 crore rupees from locations across the state. The products affected by this directive include Aciloc 150, Aciloc 150 Plus, Aciloc 300, and Aciloc 300 Plus. These formulations utilize active pharmaceutical ingredients known as API, specifically Ranitidine and Famotidine.
Mandatory Recall of Existing Market Stock
Following the inspection, the Maharashtra Food and Drug Administration has ordered Cadila Pharmaceuticals to immediately recall all available stock of these specific medicines from the market. Furthermore, a strict prohibition has been placed on the sale of both Aciloc 150 Plus and Aciloc 300 Plus. FDA Commissioner Tukaram Mundhe issued a statement highlighting that any overlap or resemblance in branding that could lead to the dispensing of incorrect medication represents a grave risk to public health. Such confusion poses a genuine danger, as patients receiving the wrong medication may face worsening health outcomes rather than the intended therapeutic benefits.
Regulatory Non-Compliance and Misleading Branding
According to Tukaram Mundhe, the company had originally received official approval only for the manufacturing of Ranitidine-based products labeled as Aciloc 150 and Aciloc 300. Subsequently, the company introduced Famotidine-based alternatives to the market under the names Aciloc 150 Plus and Aciloc 300 Plus. These new products utilized branding that was nearly identical to the original versions, inevitably creating a high potential for confusion. The Maharashtra Food and Drug Administration maintains that launching medications with different chemical compositions under similar branding violates standard regulatory guidelines.
Details of Raids and Seized Inventory
During targeted inspections conducted on July 9 and July 10, authorities raided the company’s warehouses located in the districts of Pune, Nagpur, and Bhiwandi in Thane. The operation resulted in the seizure of a total of 2,45,37,490 rupees worth of drugs. The investigation into this matter remains active, and legal proceedings will be pursued under the Drugs and Cosmetics Act, 1940, based on the final findings of the inquiry.
